India, Oct. 31 -- image credit- shutterstock

Mestastop Solutions, the Bengaluru-based biotechnology startup dedicated to stopping cancer metastasis, has formally initiated the process of approaching the US Food and Drug Administration (FDA) for an Investigational New Drug (IND) application to conduct a Phase 2 clinical study of its lead clinical candidate, MSAP031, repurposed to delay metastasis.

The candidate has already received approval from India's Central Drugs Standard Control Organisation (CDSCO) for a Phase II clinical trial in post-surgical colorectal cancer patients.

Mestastop has executed a Master Services Agreement and Work Order with Aleon Pharma International, Inc., a regulatory affairs consulting firm headquartered in Pa...